Orbimed Advisors LLC Cardiff Oncology, Inc. Transaction History
Orbimed Advisors LLC
- $3.21 Billion
- Q1 2025
A detailed history of Orbimed Advisors LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 573,884 shares of CRDF stock, worth $1.35 Million. This represents 0.06% of its overall portfolio holdings.
Number of Shares
573,884
Previous 1,538,462
62.7%
Holding current value
$1.35 Million
Previous $6.68 Million
73.02%
% of portfolio
0.06%
Previous 0.18%
Shares
2 transactions
Others Institutions Holding CRDF
# of Institutions
122Shares Held
29.5MCall Options Held
900KPut Options Held
234K-
Commodore Capital LP New York, NY5.38MShares$12.7 Million1.66% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.12MShares$7.35 Million0.0% of portfolio
-
Black Rock Inc. New York, NY2.63MShares$6.2 Million0.0% of portfolio
-
Blair William & CO Chicago, IL2.52MShares$5.96 Million0.02% of portfolio
-
Geode Capital Management, LLC Boston, MA1.5MShares$3.54 Million0.0% of portfolio
About Cardiff Oncology, Inc.
- Ticker CRDF
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,334,900
- Market Cap $102M
- Description
- Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...